REGULATORY
No PMP for Tecentriq, but Prices Rise for All 5 Checkpoint Drugs in Tax Hike Re-Pricing
August 21, 2019
Chugai Pharmaceutical’s PD-L1 inhibitor Tecentriq (atezolizumab) was found ineligible for the price maintenance premium (PMP), but all five immune checkpoint inhibitors including it will see price rises in Japan’s ad-hoc re-pricing associated with the consumption tax hike in October.According to…

LATEST

August 21, 2019
The Japanese Promotion Council for Laboratory Testing, a group of five lab test-related organizations, announced on August 20 a statement on insurance coverage for cancer gene panel tests that includes a proposal for improving the method of claiming reimbursements for…
August 21, 2019
The Ministry of Health, Labor and Welfare (MHLW) issued on August 19 a notification on drug distribution practices following the drug price revision in October associated with the upcoming consumption tax hike, asking for appropriate transactions.The notification was issued to…
August 21, 2019
The use of generic drugs cut the annual medical expenditure by 1,398.7 billion yen, but biosimilars accounted for just 14.6 billion yen of this figure, according to an estimate by the Ministry of Health, Labor and Welfare (MHLW) said on…
By Reiji Anasako

Forging ahead with its new three-year business plan, Chugai Pharmaceutical enjoyed rosy earnings in the first half of 2019, bolstered by the outperformance of the Hemlibra (emicizumab) hemophilia drug and its I/O star Tecentriq (atezolizumab). But with a biosimilar onslaught…

By Tatsuya Otsuka

Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…

By Reiji Anasako

Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…

By Yoshinori Sagehashi

As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

By Yoshinori Sagehashi

Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Philip Carrigan

Jascha Heifetz, widely regarded as one of the greatest violinists of all time, was once stopped, on 57th Street in Manhattan, by a pedestrian asking, “Could you tell me how to get to Carnegie Hall?” Heifetz pondered the question for…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA